REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough thyroid cancers: drug XL092 targets resistant tumors
Disease control Recruiting nowThis study tests a new drug called XL092 in people with advanced thyroid cancer that no longer responds to standard radioiodine therapy. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can slow or stop the cancer from spreading, an…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New hope for Hard-to-Treat thyroid cancer: which drug works best?
Disease control Recruiting nowThis study is for adults with a type of thyroid cancer that has stopped responding to standard treatment and has a specific gene change (BRAF V600E). It compares two drug approaches: cabozantinib alone versus a combination of dabrafenib and trametinib. The goal is to see which tr…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 22, 2026 14:03 UTC